Literature DB >> 23369152

Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes.

W Cheung1, H Kavnoudias, S Roberts, B Szkandera, W Kemp, K R Thomson.   

Abstract

The aims of this study were to evaluate the safety, feasibility and tumour response of _irreversible electroporation, a non-thermal ablation technique, for the treatment of unresectable hepatocellular carcinoma. The endpoints were safety and local treatment efficacy. Patients with unresectable tumours and tumours not amenable for radiofrequency _ablation because of their vicinity to organs vulnerable to thermal damage such as the bowel or because they were close to large blood vessels that would limit efficacy of ablation due to the heat sink effect were treated with irreversible electroporation using percutaneous _ultrasound and/or computed tomography guided electrode placement between November 2008 and _December 2009. Early, late, minor and major complications were recorded. Tumour response was determined on triphasic helical computed tomography follow-up at one month, then every three months post-procedure. Eleven patients received IRE therapy to 18 HCC lesions (Mean diameter 2.44 ± 0.99 cm; range 1.0-6.1 cm) with five patients having more than one treated HCC. Mean follow-up was 18 months (range 14-24 months). Six patients required repeat treatments for local residual or recurrent disease; two of these also had IRE for distant intrahepatic recurrence. No serious complications were observed despite seven lesions lying adjacent to important structures or organs. Four patients developed transient urinary retention and seven developed transient local post-procedure pain. After IRE therapy, 13 (72%) lesions were completely ablated with 93% success for lesions ≤ 3 cm (13/14). The local recurrence-free period was 18 ± 4 months and the distance recurrence free period was 14 ± 6 months. These preliminary results suggest that IRE is a safe and feasible technique for local ablation of HCC, particularly for lesions less than 3 cm. No major complications were encountered during this study even for tumours close to essential structures or organs.

Entities:  

Mesh:

Year:  2013        PMID: 23369152     DOI: 10.7785/tcrt.2012.500317

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  45 in total

Review 1.  Ablation techniques for primary and metastatic liver tumors.

Authors:  Michael J Ryan; Jonathon Willatt; Bill S Majdalany; Ania Z Kielar; Suzanne Chong; Julie A Ruma; Amit Pandya
Journal:  World J Hepatol       Date:  2016-01-28

Review 2.  Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions.

Authors:  Meaghan S Dendy; Johannes M Ludwig; Stacey M Stein; Hyun S Kim
Journal:  Liver Cancer       Date:  2019-01-16       Impact factor: 11.740

3.  Recurrence patterns following irreversible electroporation for hepatic malignancies.

Authors:  Russell C Langan; Debra A Goldman; Michael I D'Angelica; Ronald P DeMatteo; Peter J Allen; Vinod P Balachandran; William R Jarnagin; T Peter Kingham
Journal:  J Surg Oncol       Date:  2017-05-11       Impact factor: 3.454

4.  Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan.

Authors:  Katsutoshi Sugimoto; Fuminori Moriyasu; Yoshiyuki Kobayashi; Kazuhiro Saito; Hirohito Takeuchi; Saori Ogawa; Mayumi Ando; Takatomo Sano; Toshifumi Mori; Yoshihiro Furuichi; Ikuo Nakamura
Journal:  Jpn J Radiol       Date:  2015-06-02       Impact factor: 2.374

Review 5.  New horizons in ablation therapy for hepatocellular carcinoma.

Authors:  Jacob Freedman; Henrik Nilsson; Eduard Jonas
Journal:  Hepat Oncol       Date:  2015-11-06

Review 6.  Technical and practical considerations for device selection in locoregional ablative therapy.

Authors:  Sean P Zivin; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

Review 7.  Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.

Authors:  Ania Kielar; Kathryn J Fowler; Sara Lewis; Vahid Yaghmai; Frank H Miller; Hooman Yarmohammadi; Charles Kim; Victoria Chernyak; Takeshi Yokoo; Jeffrey Meyer; Isabel Newton; Richard K Do
Journal:  Abdom Radiol (NY)       Date:  2018-01

8.  Advances and Future Directions in the Treatment of Hepatocellular Carcinoma.

Authors:  Ashil J Gosalia; Paul Martin; Patricia D Jones
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-07

Review 9.  Diagnostic and therapeutic management of hepatocellular carcinoma.

Authors:  Francesco Bellissimo; Marilia Rita Pinzone; Bruno Cacopardo; Giuseppe Nunnari
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC).

Authors:  Neal Bhutiani; Prejesh Philips; Charles R Scoggins; Kelly M McMasters; Melissa H Potts; Robert C G Martin
Journal:  HPB (Oxford)       Date:  2016-05-01       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.